Collegium Pharmaceutical (COLL) PT Lowered to $48 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts COLL Hot Sheet
Price: $22.92 -1.33%
Rating Summary:
10 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
10 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Barclays analyst Glen Santangelo lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $48.00 (from $56.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Abbott Labs (ABT) PT Lowered to $125 at BTIG
- United Airlines (UAL) PT Raised to $142 at Jefferies
- Safehold (SAFE) PT Lowered to $19 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
